Analyst firms · Morgan Stanley · DGX

Morgan Stanley DGX price target and rating history

Quest Diagnostics Incorporated (DGX) · Health Care

Morgan Stanley rates Quest Diagnostics Incorporated (DGX) Overweight with a $172 price target, as of its latest action on Dec 17, 2024. It has published 5 rating actions on DGX since August 2021, including 1 upgrade and 0 downgrades.

Current rating
Overweight
Price target
$172
Median target, all firms
Too few
Actions on DGX
5

Morgan Stanley price target on DGX

$172$157$14220222023202420252026
Morgan Stanley price target on DGX, each point a stated target, August 2021 to December 2024.

Every Morgan Stanley rating on DGX

Questions about Morgan Stanley and DGX

What is Morgan Stanley's price target for DGX?
Morgan Stanley's latest stated price target for Quest Diagnostics Incorporated (DGX) is $172, from its action on Dec 17, 2024.
What is Morgan Stanley's rating on DGX?
Morgan Stanley rates DGX Overweight, a bullish rating, as of Dec 17, 2024.
When did Morgan Stanley last change its view on DGX?
On Dec 17, 2024, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $145 to $172.

More DGX rating histories

All Morgan Stanley ratingsDGX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.